Drug
CM336 (BCMA/CD3 bispecific antibody)
CM336 (BCMA/CD3 bispecific antibody) is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(20%)
Phase Distribution
Ph phase_2
2
40%
Ph not_applicable
1
20%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(4)
Terminated(1)
Detailed Status
Not yet recruiting3
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)
Trials by Status
recruiting120%
withdrawn120%
not_yet_recruiting360%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_2
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NCT07115654
not_yet_recruitingphase_2
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485
not_yet_recruitingphase_1
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004
withdrawnnot_applicable
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
NCT06769555
not_yet_recruitingphase_1
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
NCT07407010
Clinical Trials (5)
Showing 5 of 5 trials
NCT07115654Phase 2
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NCT07830485Phase 2
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07687004Phase 1
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT06769555Not Applicable
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
NCT07407010Phase 1
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5